Table 1 Patients´ characteristics and number of positive PCR results at the time of diagnosis, during a regular control after chemotherapy and during an episode of febrile neutropenia.
From: Frequency and clinical impact of viraemia in paediatric patients undergoing therapy for cancer
Malignancy | Number of patients | Age [years; median (range)] | Sex (female/male) | Total number of samples | Number and viral load* of positive samples at diagnosis of at regular during febrile malignancy control neutropenia | ||
|---|---|---|---|---|---|---|---|
ALL | 36 | 6 (1–17) | 11/25 | 185 | 2 (EBV 1 (< 500), HHV6 1 (600,000)) | 6 (HSV1/2 4 (4x < 500), HHV6 1 (13,000), CMV1 (< 200)) | 7 (CMV 2 (2x < 200); HHV6 2 (18.000/9.000); HSV1/2 2 (< 500/700); adenovirus 1 (< 500)) |
AML | 16 | 4 (8–18) | 7/9 | 75 | – | 1 (HHV6 1 (< 500)) | 3 (HHV6 2 (< 500/ < 500), CMV 1 (< 200)) |
NHL | 14 | 11 (2–18) | 5/9 | 44 | 4 (HSV1/2 1 (1.000), CMV 1 (440), HHV6 1 (150,000), EBV 1 (5000)) | 2 (HHV6 2 (14.000/14.000)) | – |
Neuroblastoma | 10 | 2 (0–5) | 7/3 | 48 | 2 (CMV 1 (< 200), EBV 1 (360)) | 3 (CMV 3 (2x < 200/290)) | 4 (CMV 3 (3x < 200), HSV1/2 1 (< 500)) |
Ewing | 3 | 15 (11–18) | 2/1 | 10 | – | – | – |
